OA06533A - Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique. - Google Patents

Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique.

Info

Publication number
OA06533A
OA06533A OA57113A OA57113A OA06533A OA 06533 A OA06533 A OA 06533A OA 57113 A OA57113 A OA 57113A OA 57113 A OA57113 A OA 57113A OA 06533 A OA06533 A OA 06533A
Authority
OA
OAPI
Prior art keywords
compounds
processes
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
OA57113A
Other languages
English (en)
Inventor
Dr Adrian Marxer
Dr Kurt Eichenberger
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of OA06533A publication Critical patent/OA06533A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA57113A 1979-05-18 1980-05-17 Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique. OA06533A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (1)

Publication Number Publication Date
OA06533A true OA06533A (fr) 1981-07-31

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
OA57113A OA06533A (fr) 1979-05-18 1980-05-17 Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique.

Country Status (21)

Country Link
EP (1) EP0019811A1 (fr)
JP (1) JPS55154971A (fr)
KR (1) KR830002757A (fr)
AR (1) AR228256A1 (fr)
AU (1) AU5848480A (fr)
DD (1) DD150609A5 (fr)
DK (1) DK214480A (fr)
ES (1) ES491514A0 (fr)
FI (1) FI801600A7 (fr)
GB (1) GB2052487B (fr)
GR (1) GR68453B (fr)
IE (1) IE49803B1 (fr)
IL (1) IL60086A (fr)
MA (1) MA18829A1 (fr)
NO (1) NO801469L (fr)
NZ (1) NZ193730A (fr)
OA (1) OA06533A (fr)
PL (1) PL224313A1 (fr)
PT (1) PT71251A (fr)
ZA (1) ZA802909B (fr)
ZW (1) ZW11880A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (de) * 1988-08-31 1990-03-01 Bayer Ag Verfahren zur herstellung von substituierten n-azinyl-n'-sulfonyl-isothioharnstoffen und n-azinyl-iminodithiokohlensaeure-s,s-diester als zwischenprodukte zu ihrer herstellung
WO1999011269A1 (fr) * 1997-09-03 1999-03-11 Eli Lilly And Company Derives de pyrimidine
WO2002022605A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2671776C (fr) * 2001-01-31 2012-12-18 H. Lundbeck A/S Antagonistes du recepteur gal3 servant a traiter une depression
MXPA04008901A (es) 2002-03-13 2004-11-26 Euro Celtique Sa Pirimidinas arilo sustituidas y el uso de las mismas.
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
US7731985B2 (en) * 2002-03-15 2010-06-08 Ciba Specialty Chemicals Corporation 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
US7601718B2 (en) 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
ATE542814T1 (de) 2005-08-18 2012-02-15 Vertex Pharma Pyrazinkinaseinhibitoren
MX2008005814A (es) 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
CA2668429A1 (fr) 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines et aminopyrimidines utiles en tant qu'inhibiteurs de proteines kinases
ES2347721T3 (es) 2006-12-19 2010-11-03 Vertex Pharmaceuticals, Inc. Aminopirimidinas utiles como inhibidores de proteina quinasas.
EP2137183B1 (fr) 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
EP2134709A1 (fr) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Utilisation des aminopyridines comme inhibiteurs de protéines kinases
AU2008226457B2 (en) 2007-03-09 2014-03-20 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
CA2694381A1 (fr) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines servant d'inhibiteurs de kinases
JP5389785B2 (ja) 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なチアゾールおよびピラゾール
NZ582879A (en) 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
MX2011002312A (es) 2008-09-03 2011-04-26 Vertex Pharma Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
RS53347B (sr) * 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2022101435A1 (fr) * 2020-11-12 2022-05-19 3Z Ehf Nouveaux traitements du trouble du déficit de l'attention/hyperactivité
CN121494792A (zh) * 2026-01-14 2026-02-10 山东国邦药业有限公司 一种5-甲氧基-4,6-二羟基嘧啶的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) * 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines

Also Published As

Publication number Publication date
FI801600A7 (fi) 1981-01-01
PL224313A1 (fr) 1981-02-13
ZA802909B (en) 1981-05-27
ZW11880A1 (en) 1980-12-17
MA18829A1 (fr) 1980-12-31
EP0019811A1 (fr) 1980-12-10
GB2052487A (en) 1981-01-28
DK214480A (da) 1980-11-19
DD150609A5 (de) 1981-09-09
AR228256A1 (es) 1983-02-15
KR830002757A (ko) 1983-05-30
IL60086A0 (en) 1980-07-31
NZ193730A (en) 1982-12-21
IL60086A (en) 1984-03-30
ES8104279A1 (es) 1981-04-16
IE49803B1 (en) 1985-12-25
NO801469L (no) 1980-11-19
JPS55154971A (en) 1980-12-02
GB2052487B (en) 1983-05-11
IE801023L (en) 1980-11-18
ES491514A0 (es) 1981-04-16
PT71251A (en) 1980-06-01
GR68453B (fr) 1981-12-30
AU5848480A (en) 1980-11-20

Similar Documents

Publication Publication Date Title
OA06533A (fr) Dérivés de la pyrimidine, procédés pour leur préparation, compositions pharmaceutiques contenant ces composés et leur utilisation thérapeutique.
OA08647A (fr) Dérivés d'imidazole, procédés pour leur préparation et composition pharmaceutique les contenant.
OA06998A (fr) Composés pharmaceutiques, leurs préparation, utilisation et intermédiaires et leur préparation.
DZ473A1 (fr) Dérivés de l'acide cis-endo-2-azabicyclo/3,3,o/-octane-3-carboxylique, procédé pour leur préparation, agents contenant ces dérivés et leur utilisation.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2708608B1 (fr) Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
SE7900685L (sv) 9-deoxi-9a-metylenisosterer av pgiŸ2 och forfarande for framstellning av dem
OA07097A (fr) Nouveaux dérivés d'arylphényléther utiles comme microbicides, procédé pour leur préparation et leur utilisation.
DZ712A1 (fr) Nouveaux dérivés de 2-2 iminobisethanol utiles comme médecaments, intermédiaires pour leur préparation et procédés pour la préparation de ces dérivés et intermédiaires.
CY2537B1 (fr) Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2422620A1 (fr) Derives du stilbene, leur preparation et leur application en tant que medicaments
OA05577A (fr) Procédé de préparation de compositions pharmaceutiques renfermant des pyréthrinoïdes.
FR2708606B1 (fr) Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2445319A1 (fr) Derives de pyridine, procedes pour leur preparation et compositions pharmaceutiques les contenant
OA07699A (fr) Dérivés de la furo-(3,4-c)-pyridine leur préparation et compositions thérapeutiques contenant ces dérivés.
DZ2188A1 (fr) Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
OA07236A (fr) Dérivés de la triazine, procédés pour leur préparation, et compositions pharmaceutiques comportant ces dérivés.
OA06651A (fr) Nouveaux dérivés de la pipéridylbenzimidazolinone, leurs procédés de préparation, les compositions pharmaceutiques les renfermant.
BE885385A (fr) Derives de d-6-n-propylergolines, leur procede de preparation et compositions pharmaceutiques en contenant
ZA783086B (en) Benzodiazepine compounds processes for their preparation,and pharmaceutical compositions thereof
FR2422657A1 (fr) 2-(2-thenoylthio)-propionylglycine, procede pour sa preparation et compositions pharmaceutiques la contenant
OA06951A (fr) Dérivés de la thiéno-pyridinone, leur procédé de préparation et leur application thérapeutique.
OA07525A (fr) Dérivés d'acides-animés, leur préparation et utilisation ainsi que les compositions contenant ces dérivés.
OA07390A (fr) Nouveaux dérivés de carbapenem, compositions pharmaceutiques les contenant, composés intermédiaires pour leur préparation, et leurs procédés de production.